Article Text

Electroacupuncture plus metformin lowers glucose levels and facilitates insulin sensitivity by activating MAPK in steroid-induced insulin-resistant rats
  1. Hsien-Yin Liao1,2,
  2. Mao-Feng Sun1,2,
  3. Jaung-Geng Lin2,
  4. Shih-Liang Chang2,3,
  5. Yu-Chen Lee1,4
  1. 1Department of Acupuncture, China Medical University Hospital, Taichung, Taiwan
  2. 2School of Chinese Medicine, China Medical University, Taichung, Taiwan
  3. 3Department of Medicinal Botanicals and Health Applications, Da-Yeh University, Changhua, Taiwan
  4. 4Graduate Institute of Acupuncture Science, China Medical University, Taichung, Taiwan
  1. Correspondence to Professor Shih-Liang Chang, Da-Yeh University, No 168, University Road, Dacun, Changhua 51591, Taiwan; slchang{at}, slc0124{at} and Yu-Chen Lee, China Medical University, No. 2, Yuh-Der Road, Taichung City, 40447, Taiwan; d5167{at}


Background Type 2 diabetes mellitus is the predominant form of diabetes. Although metformin is the preferred first-line drug for treatment of the disease, it is associated with a risk of secondary failure. Electroacupuncture (EA) can enhance insulin sensitivity and reduce blood glucose levels.

Objectives To examine, in an animal study, whether EA combined with metformin (EA–metformin) results in a better glucose-lowering effect and greater insulin sensitivity than metformin alone in steroid-induced insulin-resistant rats.

Methods Adult Wistar rats were injected with dexamethasone to induce diabetes and subsequently treated with EA plus metformin or metformin alone. Variations in plasma glucose, plasma insulin, and plasma free fatty acid levels were studied at the midpoint and end of the experimental course. Insulin receptor substrate 1 (IRS-1) and peroxisome proliferator-activated receptor γ (PPAR-γ), which are associated with glucose transporter type 4 (GLUT4) translocation, and mitogen-activated protein kinase (MAPK), which is related to GLUT4 activation, were measured after EA treatment.

Results We found that EA–metformin resulted in a better glucose-lowering effect, greater insulin sensitivity, lower plasma free fatty acid levels and higher levels of MAPK than metformin alone (p<0.05). There were no significant differences between treatment groups in expression of IRS-1 or PPAR-γ.

Conclusions The glucose-lowering effect and increased insulin sensitivity associated with EA–metformin administration is governed, at least in part, by its ability to stimulate the activation of GLUT4 via upregulation of MAPK expression.


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles